Amneal Pharmaceuticals (AMRX) investor relations material

Business evolution and diversification

• Achieved significant financial turnaround and reduced debt over the past six years.

• Diversified away from oral solid generics, now focusing on injectables, biosimilars, and specialty products.

• Affordable medicines business generates $1.5 billion in revenue, growing mid- to high-single digits.

• Oral solids' share of revenue dropped from 53% to 25% and is expected to reach 10-15% in coming years.

• 65% of ANDAs pending at FDA and 90% of R&D pipeline are focused on complex generics.

Generic injectables and product pipeline

• Injectable revenue grew from $130 million to $200 million this year, projected at $240-$250 million next year.

• Portfolio includes about 40 injectable products, with 10 new launches annually.

• Recent Omnipaque approval positions the company as the only generic provider for the 300mg dosage, with plans to expand the line.

• Omnipaque expected to impact top and bottom line from 2026 onward, with high barriers to competition.

Biosimilars growth and future opportunities

• Biosimilars business launched three years ago, now has three products and $100 million in revenue.

• Pipeline includes five new biosimilars expected to launch between 2026 and 2028.

• Denosumab launch anticipated in 2026, with XOLAIR as the largest opportunity, targeting a 2027 launch.

• XOLAIR market is $4 billion, growing 30% annually; being second to market could yield hundreds of millions in revenue.

• Current biosimilar margins are around 30% for crowded markets, up to 80% for less competitive products.